Isis Pharmaceuticals, Inc. Reports Financial Results and Highlights for 2012

CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. ISIS today announced its 2012 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2012, Isis had an NOL of $60.4 million compared to $61.3 million for 2011. Isis added a substantial amount of cash to its balance sheet throughout 2012, ending the year with nearly $375 million.